Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy
Public ClinicalTrials.gov record NCT06680479. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A5422 is a phase 1, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and immunogenicity of a vaccination with stabilized CH505 TF chTrimer admixed with 3M-052-AF + Aluminum hydroxide (Alum), to assess the effect of CH505 TF chTrimer vaccine as a therapeutic vaccine in adults living with HIV-1 on suppressive antiretroviral therapy (ART) with the aim of inducing new HIV-1 Envelope (Env) B-cell neutralizing immune responses. Participants will be on study for up to 100 weeks (52 weeks on study treatment plus 48 weeks follow-up).
Study identification
- NCT ID
- NCT06680479
- Recruitment status
- Suspended
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Interventions
- CH505 TF chTrimer Biological
- 3M-052-AF Biological
- Aluminum Hydroxide Suspension Biological
- Sodium Chloride for Injection Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2025
- Primary completion
- Apr 29, 2027
- Completion
- Apr 13, 2028
- Last update posted
- Mar 2, 2026
2025 – 2028
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Los Angeles CARE Center CRS | Los Angeles | California | 90035 | — |
| UCSD Antiviral Research Center CRS | San Diego | California | 92103 | — |
| University of California, San Francisco HIV/AIDS CRS | San Francisco | California | 94110 | — |
| Harbor University of California Los Angeles Center CRS | Torrance | California | 90502-2052 | — |
| University of Colorado Hospital CRS | Aurora | Colorado | 80045 | — |
| The Ponce de Leon Center CRS | Atlanta | Georgia | 30308-2012 | — |
| Northwestern University CRS | Chicago | Illinois | 60611 | — |
| Johns Hopkins University CRS | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital CRS (MGH CRS) | Boston | Massachusetts | 02114 | — |
| Washington University Therapeutics (WT) CRS | St Louis | Missouri | 63110-1010 | — |
| New Jersey Medical School Clinical Research Center CRS | Newark | New Jersey | 07103 | — |
| Weill Cornell Chelsea CRS | New York | New York | 10010 | — |
| Columbia Physicians & Surgeons (P&S) CRS | New York | New York | 10032 | — |
| Weill Cornell Uptown CRS | New York | New York | 10065 | — |
| University of Rochester Adult HIV Therapeutic Strategies Network CRS | Rochester | New York | 14642 | — |
| Chapel Hill CRS | Chapel Hill | North Carolina | 27599-7215 | — |
| Cincinnati CRS | Cincinnati | Ohio | 45267-0405 | — |
| Case CRS | Cleveland | Ohio | 44106 | — |
| Ohio State University CRS | Columbus | Ohio | 43210 | — |
| Penn Therapeutics CRS | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh CRS | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Therapeutics (VT) CRS | Nashville | Tennessee | 37204 | — |
| Houston Advancing Research Team CRS | Houston | Texas | 77030 | — |
| University of Washington Positive Research CRS | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06680479, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 2, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06680479 live on ClinicalTrials.gov.